Show simple item record

dc.contributor.authorWannigama, Dhammika Leshan
dc.contributor.authorSithu Shein, Aye Mya
dc.contributor.authorHurst, Cameron
dc.contributor.authorMonk, Peter N.
dc.contributor.authorHongsing, Parichart
dc.contributor.authorPhattharapornjaroen, Phatthranit
dc.contributor.authorFox Ditcham, William Graham
dc.contributor.authorOunjai, Puey
dc.contributor.authorSaethang, Thammakorn
dc.contributor.authorChantaravisoot, Naphat
dc.contributor.authorWapeesittipan, Pattama
dc.contributor.authorLuk-in, Sirirat
dc.contributor.authorSae-Joo, Sasipen
dc.contributor.authorNilgate, Sumanee
dc.contributor.authorRirerm, Ubolrat
dc.contributor.authorTanasatitchai, Chanikan
dc.contributor.authorKueakulpattana, Naris
dc.contributor.authorLaowansiri, Matchima
dc.contributor.authorLiao, Tingting
dc.contributor.authorKupwiwat, Rosalyn
dc.contributor.authorRojanathanes, Rojrit
dc.contributor.authorNgamwongsatit, Natharin
dc.contributor.authorTungsanga, Somkanya
dc.contributor.authorLeelahavanichkul, Asada
dc.contributor.authorDevanga Ragupathi, Naveen Kumar
dc.contributor.authorBadavath, Vishnu Nayak
dc.contributor.authorHosseini Rad, S.M. Ali
dc.contributor.authorKanjanabuch, Talerngsak
dc.contributor.authorHirankarn, Nattiya
dc.contributor.authorStorer, Robin James
dc.contributor.authorCui, Longzhu
dc.contributor.authorAmarasiri, Mohan
dc.contributor.authorIshikawa, Hitoshi
dc.contributor.authorHiggins, Paul G.
dc.contributor.authorStick, Stephen M.
dc.contributor.authorKicic, Anthony
dc.contributor.authorChatsuwan, Tanittha
dc.contributor.authorAbe, Shuichi
dc.date.accessioned2023-09-22T12:40:31Z
dc.date.available2023-09-22T12:40:31Z
dc.date.created2023-09-19T08:47:24Z
dc.date.issued2023
dc.identifier.issn2589-0042
dc.identifier.urihttps://hdl.handle.net/11250/3091404
dc.description.abstractDeveloping an effective therapy to overcome carbapenemase-positive Klebsiella pneumoniae (CPKp) is an important therapeutic challenge that must be addressed urgently. Here, we explored a Ca-EDTA combination with aztreonam or ceftazidime-avibactam in vitro and in vivo against diverse CPKp clinical isolates. The synergy testing of this study demonstrated that novel aztreonam-Ca-EDTA or ceftazidime-avibactam-Ca-EDTA combination was significantly effective in eliminating planktonic and mature biofilms in vitro, as well as eradicating CPKp infections in vivo. Both combinations revealed significant therapeutic efficacies in reducing bacterial load in internal organs and protecting treated mice from mortality. Conclusively, this is the first in vitro and in vivo study to demonstrate that novel aztreonam-Ca-EDTA or ceftazidime-avibactam-Ca-EDTA combinations provide favorable efficacy and safety for successful eradication of carbapenemase-producing Klebsiella pneumoniae planktonic and biofilm infections.en_US
dc.language.isoengen_US
dc.publisherCell Pressen_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/deed.no*
dc.titleCa-EDTA restores the activity of ceftazidime-avibactam or aztreonam against carbapenemase-producing Klebsiella pneumoniae infectionsen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2023 The Author(s)en_US
dc.source.articlenumber107215en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.doi10.1016/j.isci.2023.107215
dc.identifier.cristin2176301
dc.source.journaliScienceen_US
dc.identifier.citationiScience. 2023, 26 (7), 107215.en_US
dc.source.volume26en_US
dc.source.issue7en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal